US8592373B2ActiveUtilityA1
Methods for prevention and treatment of acute renal injury
Est. expiryFeb 26, 2028(~1.6 yrs left)· nominal 20-yr term from priority
A61P 13/12A61P 13/02A61K 38/07C07K 5/1019C07K 5/1016A61K 38/06A61K 38/00
93
PatentIndex Score
20
Cited by
199
References
8
Claims
Abstract
The disclosure relates to a method for protecting a kidney from renal injury. For example, acute renal injury may be associated with decreased or blocked blood flow in the subject's kidney or exposure to a nephrotoxic agent, such as a radiocontrast dye. The methods include administering to the subject an effective amount of an aromatic-cationic peptide to a subject in need thereof.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1. A method for treating contrast-induced nephropathy in a subject in need thereof, the method comprising administering to the subject an effective amount of a peptide selected from the group-consisting of Phe-D-Arg-Phe-Lys-NH 2 (SS-20) and D-Arg-2′6′Dmt-Lys-Phe-NH 2 (SS-31).
2. The method of claim 1 , wherein the contrast-induced nephropathy comprises an inflammatory response.
3. The method of claim 1 , wherein the contrast-induced nephropathy comprises a decrease in glomerular filtration rate (GFR) compared to a healthy control subject.
4. The method of claim 1 , wherein the contrast-induced nephropathy comprises a decrease in urinary output compared to a healthy control subject.
5. The method of claim 1 , wherein the contrast-induced nephropathy comprises an increase in renal tubular apoptosis compared to a healthy control subject.
6. The method of claim 1 , wherein the contrast-induced nephropathy comprises loss of renal tubular brush border and/or renal vacuolization.
7. The method of claim 1 , wherein the contrast-induced nephropathy comprises increased serum Cystatin C levels and/or serum creatinine levels compared to a healthy control subject.
8. The method of claim 1 , wherein the contrast-induced nephropathy comprises proteinuria and/or increased urinary creatinine compared to a healthy control subject.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.